Premium
IRF4 translocation status in pediatric follicular and diffuse large B‐cell lymphoma patients enrolled in Children's Oncology Group trials
Author(s) -
Chisholm Karen M.,
Mohlman Jeffrey,
Liew Michael,
Termuhlen Amanda,
Cairo Mitchell S.,
Gross Thomas G.,
Perkins Sherrie L.,
Miles Rodney R.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27770
Subject(s) - medicine , irf4 , lymphoma , follicular lymphoma , immunohistochemistry , diffuse large b cell lymphoma , bcl6 , pathology , oncology , b cell , immunology , antibody , germinal center , transcription factor , gene , biology , biochemistry
Large B‐cell lymphoma with IRF4 rearrangement is a provisional entity in the 2017 World Health Organization classification. In order to characterize these lymphomas in children from the United States, IRF4 FISH and immunohistochemical stains were performed on 32 follicular lymphoma and diffuse large B‐cell lymphoma (DLBCL) from Children's Oncology Group studies. Two DLBCLs (6%) had IRF4 rearrangements, one involving the ileocecal valve and another involving the tonsil and cerebrospinal fluid. Both cases had strong, diffuse IRF4/MUM1 immunohistochemical staining, which may be a pathologic clue to the diagnosis. Reclassification of these cases may have prognostic and therapeutic implications.